Skip to main content

Day: August 20, 2020

Muutos United Bankers -konsernin johtoryhmässä: Jyrki Thauvon jättää United Bankers -konsernin, Jukka Rasku UB Pankkiiriliike Oy:n toimitusjohtajaksi

United Bankers OyjPÖRSSITIEDOTE 20.8.2020 kello 15:00Muutos United Bankers -konsernin johtoryhmässä: Jyrki Thauvon jättää United Bankers -konsernin, Jukka Rasku UB Pankkiiriliike Oy:n toimitusjohtajaksiUB Pankkiiriliike Oy:n toimitusjohtaja Jyrki Thauvon jättää tehtävänsä United Bankers -konsernissa 31.8.2020. Jyrki Thauvon on toiminut UB Pankkiiriliikkeen (aiemmin Suomen Pankkiiriliike Oy) toimitusjohtajana vuodesta 2017. UB Pankkiiriliikkeen uudeksi toimitusjohtajaksi on nimitetty KTM Jukka Rasku. Hän aloittaa United Bankers -konsernin johtoryhmän jäsenenä aiemmin tiedotetun mukaisesti 24.8.2020 alkaen ja toimitusjohtajana 1.9.2020.”United Bankers hankki Suomen Pankkiiriliikkeen koko osakekannan vuonna 2018. Jyrki on ollut tätä seuranneella ajanjaksolla mukana edistämässä työtämme organisaatioiden yhdistämisessä. Haluan kiittää Jyrkiä...

Continue reading

Piippo Oyj puolivuotiskatsaus 1.1.-30.6.2020: Piippo Oyj:n alkuvuoden liikevaihto kasvoi ja liiketulos pysyi edellisen vuoden tasolla

PIIPPO OYJPUOLIVUOTISKATSAUS 1.1.-30.6.2020(tilintarkastamaton)Piippo Oyj:n alkuvuoden liikevaihto kasvoi ja liiketulos pysyi edellisen vuoden tasollaTammi-kesäkuun 2020 pääkohdatYhtiön agrituotteiden toimitukset ovat painottuneet perinteisesti ensimmäiselle vuosipuoliskolle, tuotannon toimiessa tasaisesti läpi vuoden. Yhtiö valmistaa toisen vuosipuoliskon aikana tuotteita myös varastoon uudelle alkavalle sesongille. Toimialalla uusi agrisesonki alkaa vuosittain lokakuussa ja päättyy seuraavana vuonna syyskuun loppuun. Yhtiön tilikausi noudattaa kuitenkin kalenterivuotta.Tammi-kesäkuun 2020 yhteenveto (tammi-kesäkuu 2019):Liikevaihto 10,8 milj.€ (10,2 milj.€), jossa kasvua 6,5 %Liiketulos 0,4 milj.€ (0,4 milj.€)Katsauskauden tulos 0,3 milj.€ (0,2 milj.€)Liiketoiminnan rahavirta oli 0,2 milj.€ positiivinen (-0,4 milj.€ negatiivinen), parantuneen...

Continue reading

Navios Maritime Holdings Inc. Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2020

Revenue$188.2 million for H1 2020$97.1 million for Q2 2020Cash from operating activities$5.5 million for H1 2020$7.0 million for Q2 2020Adjusted EBITDA (a non-GAAP measure)$55.9 million for H1 2020$27.2 million for Q2 2020Liquidation of Navios Europe IITwo drybulk vessels and $7.9 million from Navios Europe II liquidationSold two vessels with an average age of 15.0 years for $14.1 millionNavios Logistics issued $500.0 million 10.75% Senior Secured Notes due 2025MONACO, Aug. 20, 2020 (GLOBE NEWSWIRE) — Navios Maritime Holdings Inc. (“Navios Holdings” or “the Company”) (NYSE: NM), a global seaborne shipping and logistics company, today reported financial results for the second quarter and six month period ended June 30, 2020.Angeliki Frangou, Chairman and Chief Executive Officer, stated, “The pandemic has greatly affected businesses,...

Continue reading

Trevena Announces Receipt of Milestone Payment Under Partnership in China With Jiangsu Nhwa Pharmaceutical Co.

—$3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injectionAdditional approval and commercialization milestone payments expected as well as 10% royalties on net sales in China—CHESTERBROOK, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has a received a $3 million milestone payment from its partner in China for the U.S. approval of OLINVYK. Nhwa holds an exclusive license agreement to develop, manufacture, and commercialize OLINVYK in China.“With U.S. approval of OLINVYK now in hand, I am pleased that our ex-U.S. partnerships also continue to make meaningful progress,” said Carrie Bourdow, President and...

Continue reading

Iconic omnichannel retailer expands next-gen digital customer experiences with eGain

SUNNYVALE, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), the leading provider of customer engagement solutions, today announced that a leading omnichannel retailer is now offering expanded self-service powered by eGain.The company selected eGain for its deep product capabilities and quick business value. With shoppers going digital in a hurry in the pandemic, the company needed to rapidly expand customer self-service, while controlling operating costs.In a matter of weeks, eGain helped launch virtual assistance and customer messaging to complement existing live chat and knowledge-based customer engagement. Going beyond “meet and greet,” the virtual assistant resolves a broad range of questions on orders, returns, product selection, and store location. Integrated with transactional systems, it now successfully resolves...

Continue reading

Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis

First healthy volunteer dosed in a Phase 1 study of AQST-108 for the treatment of allergic reactions including anaphylaxisPharmacokinetic and pharmacodynamics data expected in fourth quarter 2020WARREN, N.J., Aug. 20, 2020 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today the initiation of a Phase 1 Pharmacokinetic (PK) trial for the Company’s drug candidate AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of allergic reactions (Type 1), including anaphylaxis, using Aquestive’s proprietary PharmFilm® technologies. “The initiation of this Phase 1 trial represents...

Continue reading

Conformis Announces Achievement of Second Milestone Under Development and License Agreements

BILLERICA, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) announced today that it completed the second of three milestones pursuant to the License Agreement and Development Agreement with Howmedica Osteonics Corp., a wholly owned subsidiary of Stryker Corporation also known as Stryker Orthopaedics, under which Conformis is developing patient-specific instrumentation (“PSI”) for use in connection with Stryker’s knee implant offerings. The Company will receive an additional $3.0 million from Stryker for achieving this milestone.“We are pleased to announce the achievement of the second project milestone,” said Mark Augusti, President and Chief Executive Officer. “We believe that this project, as well as the long-term distribution agreement under which Conformis will manufacture and supply PSI to Stryker, will...

Continue reading

Marathon Gold Appoints Lead Consultant for Valentine Feasibility Study

TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) is pleased to announce the appointment of Ausenco Engineering Canada Inc. (“Ausenco”) as the lead consultant for the Feasibility Study (“FS”) at the Valentine Gold Project in central Newfoundland.As lead consultant for the FS, Ausenco will be responsible for process and facilities design, access and power infrastructure design, capital and operating cost estimation and execution planning. As project manager of the FS, Ausenco will also be coordinating contractor engagement, with a strong focus on local procurement, service providers, and employment. Working in coordination with Ausenco, Marathon has also engaged Moose Mountain Technical Services for open pit mine design, site infrastructure design (waste rock piles and haul...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.